Regeneron hands off certain Libtayo rights in Europe to Medison Pharma

After Regeneron took over full Libtayo rights from former partner Sanofi, Medison is now set to commercialize the oncology med in certain European and international markets.

Medison boasts an international commercialization platform and focuses on broadening the reach of therapies such as Libtayo, the company said in a release.